Printer Friendly

SCICLONE PHARMACEUTICALS RECEIVES APPROVAL TO MARKET ZADAXIN(TM) IN SINGAPORE

 SAN MATEO, Calif., Oct. 13 /PRNewswire/ -- SciClone Pharmaceuticals Inc. (NASDAQ: SCLN) today announced that its lead drug Zadaxin(TM) thymosin alpha 1 has received marketing approval from the Ministry of Health of the Republic of Singapore for the treatment of chronic hepatitis B. The product license is being issued under comparable circumstances to the U.S. Food and Drug Administration's (FDA) accelerated marketing approval of certain new drugs and biological products for serious or life-threatening illnesses, with provisions for continued study of the drug's clinical benefits and restriction on use if necessary. The license has provisions for a surveillance program.
 "This is a major achievement for SciClone," said Don Sellers, SciClone's managing director of Pacific Rim Operations. "It is gratifying to receive our first approval for Zadaxin in Singapore as it is the economic and medical center for Southeast Asia, and widely regarded as the region's leader in healthcare technology. We also are very pleased that Zadaxin has been approved by the Ministry as a means to help combat chronic hepatitis B. In Singapore the disease is a serious health problem, as in the rest of Southeast Asia where there are over 35 million carriers of the hepatitis B virus. It is estimated that 100,000 of Singapore's three million people have the chronic hepatitis B disease."
 Thymosin alpha 1 is a naturally occurring 28 amino acid peptide originally discovered in the thymus gland, which has been used in clinical trials as an immune modulator for the treatment of hepatitis B. The compound is produced through chemical synthesis. As announced previously, SciClone has entered into an agreement with Sclavo S.p.A. (Italy) under which finished and vialed Zadaxin could be available by the end of the year. However, the assurance of a timely supply of active ingredient is a subject of the current arbitration between SciClone and its licensor and supplier, Alpha 1 Biomedicals Inc.
 SciClone Pharmaceuticals Inc. of San Mateo is primarily engaged in the acquisition, development and marketing of pharmaceuticals on a worldwide basis. The company's primary focus is on the development of therapeutics for infectious diseases including hepatitis B, cancers and immune system disorders that are life threatening and place major cost burdens on the world's healthcare system.
 -0- 10/13/93
 /CONTACT: Michelle E. Slade, manager of corporate communications, or SciClone Pharmaceuticals, 415-358-3456/
 (SCLN)


CO: SciClone Pharmaceuticals Inc. ST: California IN: MTC SU:

TM-PK -- SF006 -- 1724 10/13/93 13:25 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1993
Words:407
Previous Article:BIOJECT EXPANDS PHYSICIAN OFFICE DISTRIBUTION WITH TAYLOR MEDICAL
Next Article:J.M. PETERS CO. INC. NEWS RELEASE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters